Launch of MoonLake Immunotherapeutics with in-license of Merck's IL-17 nanobody

4 May 2021
merck_kgaa_new_large

Newly-established Swiss biotech MoonLake Immunotherapeutics has in-licensed the tri-specific nanobody sonelokimab (M1095/ALX 0761) from Germany’s Merck KGaA (MRK: DE).

MoonLake has been set up by an international team of immunology specialists to leverage revolutionary nanobody (single-domain antibody) technology in multiple indications. It will accelerate the clinical development of sonelokimab, building on robust clinical data generated by Merck and by Ablynx, a Sanofi (Euronext: SAN) company, which discovered the molecule. No financial terms of the accord are disclosed.

Sonelokimab has clinically demonstrated potential to drive disease modification in dermatology and rheumatology patients. Sonelokimab is a tri-specific, balanced interleukin (IL)-17A/F inhibitor with an albumin binding site, which has the potential to facilitate deep tissue penetration in the skin and joints.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology